 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Interneuron Pharmaceuticals, Inc.
 |
Interneuron Pharmaceuticals, Inc. |
 |
 |
 |
PROFILE |
 |
Call it rebound, redux: Interneuron Pharmaceuticals is bouncing back from its Redux catastrophe with new products and alliances. The company withdrew the diet drug, sold by American Home Products (AHP) subsidiary Wyeth-Ayerst, from the market in 1997 after it was linked to heart failure. Despite being hit hard by Redux-related lawsuits and setbacks to its drug pipeline, the company is plugging on with its lead drug candidate, Pagoclone, for anxiety attacks. Other drugs in development include LidodexNS for migraine headaches and Citicoline for stroke. The company and AHP have reached a settlement over the latter's failure to disclose studies showing heart problems in fen-phen users that could be related to Redux.
COMPETITION |
 |
American Home Products Corporation (AHP)
GlaxoSmithKline plc (GSK)
Pharmacia Corporation (PHA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 27.80
1-Yr. Sales Growth: 1,637.5%
Employees: 18
Revenue per employee: $1,544,444.44
KEY PEOPLE |
 |
Glenn L. Cooper
CEO
Michael W. Rogers
CFO
CONTACT INFO |
 |
1 Ledgemont Center, 99 Hayden Ave.
Lexington, MA 02421
US
Phone: 781-861-8444
Fax: 781-861-3830
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |